fda and tirzepatide shortage Breaking News: Compounding Pharmacies Take the Fight to the Fifth Circuit The Outsourcing Facilities Association (OFA) has filed an appeal challenging the FDA's decision to restrict compounding pharmacies from producing tirzepatide, the FDA confirms tirzepatide shortage is

However, the future of pharmacies abilities to make compounded GLP-1 medications is uncertain

They just make temporary disruption more likely while your body adjusts to tirzepatide

Increased inflammation, a root of nearly all chronic disease, including heart disease

Cogswell, J

Some potential side effects associated with the human use of PT-141 may include nausea, flushing, headaches, and increased blood pressure, mostly observed when injecting PT-141

A total of 16,687 non-serious reports of adverse effects from tirzepatitde were made to the MHRA in 2025 either through the Yellow Card scheme or by the pharmaceutical industry